29 results on '"Suruga, Y."'
Search Results
2. G-CSF INVOLVEMENT IN THE GROWTH OF PRIMARY ATL CELLS AND HTLV-I INFECTED T CELLS
- Author
-
Matushita, K., primary, Arima, N., additional, Ohtsubo, H., additional, Arimura, K., additional, Kukita, T., additional, Fujiwara, H., additional, Suruga, Y., additional, Hidaka, S., additional, and Tei, C., additional
- Published
- 1999
- Full Text
- View/download PDF
3. Vesnarinone inhibits growth of small cell lung cancer cell lines via induction of apoptosis
- Author
-
Yamaguchi, A., primary, Arima, N., additional, Mori, H., additional, Matsishita, K., additional, Arimura, K., additional, Fujiwara, H., additional, Suruga, Y., additional, Kawamata, N., additional, Ymada, H., additional, and Tanaka, H., additional
- Published
- 1997
- Full Text
- View/download PDF
4. Mechanism of inhibition by piperazinyloxoquinoline derivatives as novel HIV-1 transcription inhibitors
- Author
-
Okamoto, M., primary, Suruga, Y., additional, Makino, M., additional, Kimura, Y., additional, Ikeuchi, T., additional, Sakaguchi, T., additional, Okamoto, T., additional, and Baba, M., additional
- Published
- 1997
- Full Text
- View/download PDF
5. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus.
- Author
-
Akimoto M, Matsushita K, Suruga Y, Aoki N, Ozaki A, Uozumi K, Tei C, and Arima N
- Published
- 2007
6. NF-@kB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications - last pieces in the NF-@kB puzzle?
- Author
-
Arima, N., Matsushita, K., Obata, H., Ohtsubo, H., Fujiwara, H., Arimura, K., Kukita, T., Suruga, Y., Wakamatsu, S., and Hidaka, S.
- Published
- 1999
- Full Text
- View/download PDF
7. Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
- Author
-
Makino, M, Azuma, M, Wakamatsu, S I, Suruga, Y, Izumo, S, Yokoyama, M M, and Baba, M
- Abstract
In a search for new anti-autoimmune agents that selectively suppress activation of autoreactive T cells, one such agent, 5-methyl-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide (CI-959-A), was found to be effective. This compound, which is known to suppress tumor necrosis factor alpha (TNF-alpha)-induced CD54 expression, inhibited the primary proliferative response of the T cell to antigen (Ag)-presenting cells (APCs) including allogenic dendritic cells (DCs), autologous Epstein-Barr virus-infected B cells, and human T lymphotropic virus type I (HTLV-I)-infected T cells. Autoreactive T cells from patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) spontaneously proliferate in vitro, and their activation is reported to be associated with CD54 expression. The spontaneous proliferation of T cells from patients with HAM/TSP was entirely blocked by CI-959-A. However, in this study, the T-cell proliferation in 15 patients with HAM/TSP was found to depend more extensively on major histocompatibility complex (MHC) class II and CD86 than on CD54 Ags. Since most important APCs for the development of HAM/TSP are DCs and HTLV-I-infected T cells, the effect of CI-959-A on DC generation and on the expression of surface molecules on activated T cells is examined. CI-959-A suppressed recombinant granulocyte-macrophage colony stimulating factor (GM-CSF)- and recombinant interleukin-4-dependent differentiation of DCs from monocytes and inhibited the expression of CD54 and, more extensively, MHC class II and CD86 Ags. CI-959-A showed little toxicity toward lymphoma or HTLV-I-infected T-cell lines or toward monocytes and cultured DCs. These results suggest that CI-959-A might be a potent anti-HAM/TSP agent.
- Published
- 1999
8. aIL-2-induced growth of CD8^+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor a expression
- Author
-
Arima, N., Matsushita, K., Suruga, Y., Ohtsubo, H., Fujiwara, H., Hidaka, S., Arimura, K., Kukita, M., Yamaguchi, K., and Fukumori, J.
- Published
- 1998
- Full Text
- View/download PDF
9. Tectal glioma: clinical, radiological, and pathological features, and the importance of molecular analysis.
- Author
-
Imoto R, Otani Y, Fujii K, Ishida J, Hirano S, Kemmotsu N, Suruga Y, Mizuta R, Kegoya Y, Inoue Y, Umeda T, Hokama M, Washio K, Yanai H, Tanaka S, Satomi K, Ichimura K, and Date I
- Abstract
Tectal glioma (TG) is a rare lower grade glioma (LrGG) that occurs in the tectum, mainly affecting children. TG shares pathological similarities with pilocytic astrocytoma (PA), but recent genetic analyses have revealed distinct features, such as alterations in KRAS and BRAF. We conducted a retrospective review of cases clinically diagnosed as TG and treated at our institute between January 2005 and March 2023. Six cases were identified and the median age was 30.5 years. Four patients underwent biopsy and two patients underwent tumor resection. Histological diagnoses included three cases of PA, one case of astrocytoma, and two cases of high-grade glioma. The integrated diagnosis, according to the fifth edition of the World Health Organization Classification of Tumours of the central nervous system, included two cases of PA and one case each of diffuse high-grade glioma; diffuse midline glioma H3 K27-altered; glioblastoma; and circumscribed astrocytic glioma. Among the three patients who underwent molecular evaluation, two had KRAS mutation and one had H3-3A K27M mutation. Our results demonstrate the diverse histological and molecular characteristics of TG distinct from other LrGGs. Given the heterogeneous pathological background and the risk of pathological progression in TG, we emphasize the importance of comprehensive diagnosis, including molecular evaluation., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. New Anti-Angiogenic Therapy for Glioblastoma With the Anti-Depressant Sertraline.
- Author
-
Tsuboi N, Otani Y, Uneda A, Ishida J, Suruga Y, Matsumoto Y, Fujimura A, Fujii K, Matsui H, Kurozumi K, Date I, and Michiue H
- Subjects
- Animals, Mice, Humans, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Brain Neoplasms metabolism, Neovascularization, Pathologic drug therapy, Cell Line, Tumor, Antidepressive Agents pharmacology, Antidepressive Agents therapeutic use, Cell Differentiation drug effects, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor A antagonists & inhibitors, Drug Resistance, Neoplasm drug effects, Xenograft Model Antitumor Assays, Drug Repositioning, Disease Models, Animal, Glioblastoma drug therapy, Glioblastoma pathology, Glioblastoma metabolism, Sertraline pharmacology, Sertraline therapeutic use, Angiogenesis Inhibitors pharmacology, Angiogenesis Inhibitors therapeutic use, Endothelial Cells drug effects, Endothelial Cells metabolism
- Abstract
Background and Aims: Anti-angiogenic therapies prolong patient survival in some malignancies but not glioblastoma. We focused on the relationship between the differentiation of glioma stem like cells (GSCs) into tumor derived endothelial cells (TDECs) and, anti-angiogenic therapy resistance. Especially we aimed to elucidate the mechanisms of drug resistance of TDECs to anti-angiogenic inhibitors and identify novel anti-angiogenic drugs with clinical applications., Results: The mouse GSCs, 005, were differentiated into TDECs under hypoxic conditions, and TDECs had endothelial cell characteristics independent of the vascular endothelial growth factor (VEGF) pathway. In vivo, inhibition of the VEGF pathway had no anti-tumor effect and increased the percentage of TDECs in the 005 mouse model. Novel anti-angiogenic drugs for glioblastoma were evaluated using a tube formation assay and a drug repositioning strategy with existing blood-brain barrier permeable drugs. Drug screening revealed that the antidepressant sertraline inhibited tube formation of TDECs. Sertraline was administered to differentiated TDECs in vitro and 005 mouse models in vivo to evaluate genetic changes by RNA-Seq and tumor regression effects by immunohistochemistry and MRI. Sertraline reduced Lama4 and Ang2 expressions of TDEC, which play an important role in non-VEGF-mediated angiogenesis in tumors. The combination of a VEGF receptor inhibitor axitinib, and sertraline improved survival and reduced tumor growth in the 005 mouse model., Conclusion: Collectively, our findings showed the diversity of tumor vascular endothelial cells across VEGF and non-VEGF pathways led to anti-angiogenic resistance. The combination of axitinib and sertraline can represent an effective anti-angiogenic therapy for glioblastoma with safe, low cost, and fast availability., (© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
11. Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study.
- Author
-
Tomita Y, Hibler EA, Suruga Y, Ishida J, Fujii K, Satomi K, Ichimura K, Hirotsune N, Date I, Tanaka Y, and Otani Y
- Subjects
- Child, Adult, Humans, Aged, Infant, Newborn, Infant, Child, Preschool, Adolescent, Young Adult, Aged, 80 and over, Middle Aged, SEER Program, Incidence, Prognosis, Astrocytoma epidemiology, Central Nervous System Neoplasms
- Abstract
Background Pilocytic astrocytomas (PAs) are central nervous system tumors with variable prognosis and poorly understood risk factors. Little evidence exists regarding the effect of age on mortality in PA. Therefore, we conducted a thorough characterization of PA in the US. Methods We queried the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2018 to extract age-adjusted incidence rate (AAIR), age-adjusted mortality rate (AAMR), and survival data on PA. The age group comparisons for each measure varied depending on available SEER data. We compared trends in AAIR and AAMR by two age groups (children, 0-19 years; adults, 20 + years) and by sex. The cumulative incidence function and the Fine-Gray competing risk model were applied by 0-19, 20-39, 40-59, and 60 + years of age groups. Results This study included 5211 incident PA and 462 PA-specific deaths between 2000 and 2018. Trends in AAIRs and AAMRs were almost constant between 2000 and 2018. Average AAIRs had a sharp peak in 1-4 years of age groups, whereas AAMRs had a gradual peak in 80-84 years of age groups. Age groups, tumor location, and race/ethnicity were significantly associated with PA-specific death, whereas only age was associated with other cause of deaths. Conclusions Trends in AAIRs and AAMRs were constant regardless of age. PAs in older populations, especially over 60 years old, have higher incidence of death than those in younger populations., (© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
12. Utility of Comprehensive Genomic Profiling for Precise Diagnosis of Pediatric-Type Diffuse High-Grade Glioma.
- Author
-
Makino K, Otani Y, Fujii K, Ishida J, Hirano S, Suruga Y, Washio K, Nishida K, Yanai H, Tomida S, Ennishi D, and Date I
- Subjects
- Male, Humans, Child, Adolescent, Temozolomide, Mutation, Genomics, Glioma diagnosis, Glioma genetics, Brain Neoplasms diagnosis, Brain Neoplasms genetics, Brain Neoplasms pathology
- Abstract
In the current World Health Organization classification of central nervous system tumors, comprehensive genetic and epigenetic analyses are considered essential for precise diagnosis. A 14-year-old male patient who presented with a cerebellar tumor was initially diagnosed with glioblastoma and treated with radiation and concomitant temozolomide chemotherapy after resection. During maintenance temozolomide therapy, a new contrast-enhanced lesion developed in the bottom of the cavity formed by the resection. A second surgery was performed, but the histological findings in specimens from the second surgery were different from those of the first surgery. Although genome-wide DNA methylation profiling was conducted using frozen tissue for a precise diagnosis, the proportion of tumor cells was insufficient and only normal cerebellum was observed. We then performed comprehensive genetic analysis using formalin-fixed paraffin-embedded sections, which revealed MYCN amplification without alteration of IDH1, IDH2, or Histone H3. Finally, the patient was diagnosed with pediatric-type diffuse high-grade glioma, H3-wildtype and IDH-wildtype. In conclusion, comprehensive genetic and epigenetic analysis should be considered in pediatric brain tumor cases., Competing Interests: No potential conflict of interest relevant to this article was reported.
- Published
- 2023
- Full Text
- View/download PDF
13. Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.
- Author
-
Otani Y, Satomi K, Suruga Y, Ishida J, Fujii K, Ichimura K, and Date I
- Subjects
- Adult, Humans, Child, DNA Methylation genetics, Precision Medicine, Brain Neoplasms diagnosis, Brain Neoplasms genetics, Brain Neoplasms pathology, Glioma diagnosis, Glioma genetics, Glioma pathology, Central Nervous System Neoplasms genetics
- Abstract
Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient's outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in the clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed., (© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.)
- Published
- 2023
- Full Text
- View/download PDF
14. The utility of DNA methylation analysis in elderly patients with pilocytic astrocytoma morphology.
- Author
-
Suruga Y, Satomi K, Otani Y, Fujii K, Ishida J, Uneda A, Tsuboi N, Makino K, Hirano S, Kemmotsu N, Imoto R, Mizuta R, Tomita Y, Yasuhara T, Washio K, Yanai H, Matsushita Y, Hibiya Y, Yoshida A, Capper D, Ichimura K, and Date I
- Subjects
- Humans, Aged, Child, Preschool, Child, Adolescent, Young Adult, Adult, Middle Aged, Aged, 80 and over, DNA Methylation, Retrospective Studies, Mutation, Isocitrate Dehydrogenase genetics, Brain Neoplasms pathology, Astrocytoma pathology
- Abstract
Purpose: Pilocytic astrocytoma (PA) is a circumscribed low-grade astrocytic glioma, generally considered to be associated with a good prognosis. However, a subset of PA patients shows unfavorable outcomes. In this study, we retrospectively reviewed PA patients and performed further molecular analysis, such as DNA methylation profiling, to identify prognostic factors., Methods: We analyzed 29 histologically-confirmed PA patients from a single center from 2002 to 2021 and conducted integrated molecular analyses among elderly PA patients since age was an independent prognostic factor for poor outcomes., Results: The median age at diagnosis was 14 years (range 3-82 years) and 4 patients (14%) were elderly (patients ≥ 60 years old). Age over 60 was associated with poor progression-free survival and overall survival. We performed DNA methylation analysis on 2 of the 4 elderly patients. Both cases were histologically diagnosed as PA, but DNA methylation profiling revealed one as high-grade astrocytoma with piloid features (all methylation class scores were below 0.3 in both v11b4 and v12.5) and the other as glioblastoma, IDH-wildtype (score was over 0.5 in both v11b4 and v12.5), using the German Cancer Research Center methylation profiling classifiers and t-SNE analysis., Conclusions: Elderly patients with PA morphology showed unfavorable outcomes in this cohort. In those patients, further molecular analysis and DNA methylation profiling revealed the possibility of high-grade astrocytic tumors, including newly defined entities., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
15. Pyogenic Ventriculitis After Anterior Skull Base Surgery Treated With Endoscopic Ventricular Irrigation And Reconstruction Using a Vascularized Flap.
- Author
-
Tomita Y, Shimazu Y, Kawakami M, Matsumoto H, Fujii K, Kameda M, Yasuhara T, Suruga Y, Ota T, Kimata Y, Kurozumi K, and Date I
- Subjects
- Humans, Male, Middle Aged, Therapeutic Irrigation, Cerebral Ventriculitis etiology, Craniotomy adverse effects, Surgical Wound Infection etiology
- Abstract
Ventriculitis is a rare, serious complication of neurosurgery. A 59-year-old man who had undergone a craniotomy for a paranasal adenocarcinoma, developed a right frontal cystic lesion. We performed a bifrontal craniotomy to remove the lesion. The dura was repaired with non-vascularized free fascia lata in watertight fashion. Ventriculitis occurred 3 days postoperatively. Ventricular drainage, craniectomy, and endoscopic irrigation were undertaken to remove an abscess. The dura and the resection cavity were reconstructed using a vascularized anterolateral thigh adipofascial flap. His symptoms disappeared, indicating that endoscopic irrigation and reconstruction can effectively address ventriculitis even in patients in critical clinical condition., Competing Interests: No potential conflict of interest relevant to this article was reported.
- Published
- 2021
- Full Text
- View/download PDF
16. 4-Hydroxyl-2-Nonenal Localized Expression Pattern in Retrieved Clots is Associated with Large Artery Atherosclerosis in Stroke Patients.
- Author
-
Osakada Y, Yamashita T, Morihara R, Matsumoto N, Sasaki R, Tadokoro K, Nomura E, Kawahara Y, Omote Y, Hishikawa N, Takemoto M, Ohta Y, Suruga Y, Nagase T, Takasugi Y, Inoue S, Watanabe K, Deguchi K, Tokunaga K, Sasada S, Kobayashi K, Maeoka R, Fukutome K, Takahashi K, Ohnishi H, Kuga Y, Ohnishi H, and Abe K
- Subjects
- Aged, Aged, 80 and over, Biomarkers analysis, Embolic Stroke diagnosis, Embolic Stroke metabolism, Embolic Stroke therapy, Female, Humans, Intracranial Thrombosis diagnosis, Intracranial Thrombosis metabolism, Intracranial Thrombosis therapy, Ischemic Stroke diagnosis, Ischemic Stroke metabolism, Ischemic Stroke therapy, Male, Middle Aged, Risk Factors, Thrombectomy, Aldehydes analysis, Embolic Stroke etiology, Intracranial Thrombosis etiology, Ischemic Stroke etiology, Oxidative Stress
- Abstract
Objectives: The relationship between stroke etiology and clot pathology remains controversial., Materials and Methods: We performed histological analysis of clots retrieved from 52 acute ischemic stroke patients using hematoxylin and eosin staining and immunohistochemistry (CD42b and oxidative/hypoxic stress markers). The correlations between clot composition and the stroke etiological group (i.e., cardioembolic, cryptogenic, or large artery atherosclerosis) were assessed., Results: Of the 52 clots analyzed, there were no significant differences in histopathologic composition (e.g., white blood cells, red blood cells, fibrin, and platelets) between the 3 etiological groups (P = .92). By contrast, all large artery atherosclerosis clots showed a localized pattern with the oxidative stress marker 4-hydroxyl-2-nonenal (P < .01). From all 52 clots, 4-hydroxyl-2-nonenal expression patterns were localized in 28.8% of clots, diffuse in 57.7% of clots, and no signal in 13.5% of clots., Conclusions: A localized pattern of 4-hydroxyl-2-nonenal staining may be a novel and effective marker for large artery atherosclerosis (sensitivity 100%, specificity 82%)., Competing Interests: Declaration of Competing Interest The authors declare that they have no conflicts of interest., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
17. A Patient with a Cavernous Sinus Dural Arteriovenous Fistula in Whom an Approach through the Jugular Venous Arch Involving Facial Vein Return Was Adopted.
- Author
-
Nagase T, Tokunaga K, Watanabe K, Umeda T, Suruga Y, Takasugi Y, Inoue S, Kiriyama H, and Matsumoto K
- Abstract
Objective: We report the case of a cavernous sinus dural arteriovenous fistula (CSdAVF) treated by transvenous embolization (TVE) via the jugular venous arch (JVA) connecting bilateral superficial cervical veins., Case Presentation: A male patient in his 50s presenting with diplopia and headache was diagnosed with a CSdAVF. The first session of TVE resulted in incomplete obliteration of the fistula due to poor accessibility through the inferior petrosal sinus (IPS), and postoperative computed tomography angiography (CTA) disclosed a newly developed drainage route into the facial vein (FV) connecting to the anterior jugular vein (AJV) and the JVA. The patient underwent the second session of TVE through the JVA, FV, and the superior ophthalmic vein (SOV), and obliteration was achieved., Conclusion: There is a considerable variation in the anatomy of facio-cervical veins in patients with CSdAVF. Meticulous preoperative evaluation of the venous drainage route using modern diagnostic tools is indispensable to achieve successful results in patients with CSdAVF., Competing Interests: The authors declare no conflict of interest., (©2021 The Japanese Society for Neuroendovascular Therapy.)
- Published
- 2021
- Full Text
- View/download PDF
18. Practical Use of a Communication Application on Mobile Devices by Our Stroke Team.
- Author
-
Tokunaga K, Inoue S, Suruga Y, Nagase T, Takagi Y, Watanabe K, Kiriyama H, Deguchi S, Deguchi K, and Matsumoto K
- Abstract
Objective: To describe our 1-year experience of the practical use of a mobile communication application by our stroke team., Methods: The mobile Join application (Allm Inc., Tokyo, Japan) was introduced into our stroke team for the purpose of immediate sharing of the patient information. We analyzed the usage situation for 1 year after the introduction of Join, particularly its efficacy in improving the door-to-puncture time (D2P) for thrombectomy cases, and reported our inter-hospital collaboration with the use of Join., Results: The total number of events notified by Join was 337, and they included acute stroke potentially leading to reperfusion therapy in 23% (76 events), head trauma in 14%, brain hemorrhage in 12%, other infarction in 10%, subarachnoid hemorrhage in 8%, and the others in 34%. The information of the patients was shared among the team members before arrival to our hospital in 42% of acute stroke cases. Of 31 patients undergoing mechanical thrombectomy, the median interval between arrival and groin puncture for the directly transported patients with/without pre-hospital information was 77.5 min/87 min, respectively, whereas that of the patients transferred from primary hospitals with/without pre-hospital information was 19 min/71 min (p <0.0001), respectively, demonstrating the efficacy of information sharing in advance through Join in improving the timing of endovascular therapy. For inter-hospital collaboration using the telestroke system, we concluded the partnership agreement with three local primary hospitals by communication via Join at a reasonable cost., Conclusion: Active and effective utilization of the mobile Join application for communication by our stroke team was demonstrated, and it is expected to promote inter-hospital collaboration in stroke treatment., Competing Interests: The first author and the co-authors have no conflicts of interest., (©2020 The Japanese Society for Neuroendovascular Therapy.)
- Published
- 2020
- Full Text
- View/download PDF
19. Pulmonary Nocardiosis: A Clinical Analysis of 30 Cases.
- Author
-
Takiguchi Y, Ishizaki S, Kobayashi T, Sato S, Hashimoto Y, Suruga Y, and Akiba Y
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Female, Humans, Immunocompromised Host, Immunosuppressive Agents administration & dosage, Japan, Lung Diseases, Interstitial complications, Male, Middle Aged, Neoplasms complications, Nocardia classification, Nocardia isolation & purification, Nocardia Infections complications, Nocardia Infections diagnosis, Opportunistic Infections complications, Pulmonary Disease, Chronic Obstructive complications, Retrospective Studies, Vascular Diseases complications, Nocardia Infections physiopathology
- Abstract
Objective Pulmonary nocardiosis frequently develops as an opportunistic infection in patients with malignant tumor and is treated with steroids. This study was performed to clarify the clinical features of pulmonary nocardiosis in Japan. Methods The patients definitively diagnosed with pulmonary nocardiosis at our hospital between January 1995 and December 2015 were retrospectively investigated. Results Nineteen men and 11 women (30 in total) were diagnosed with pulmonary nocardiosis. Almost all patients were complicated by a non-pulmonary underlying disease, such as malignant tumor or collagen vascular disease, or pulmonary disease, such as chronic obstructive pulmonary disease or interstitial pneumonia, and 13 patients (43.3%) were treated with steroids or immunosuppressors. Gram staining was performed in 29 patients, and a characteristic Gram-positive rod was detected in 28 patients (96.6%). Thirty-one strains of Nocardia were isolated and identified. Seven strains of Nocardia farcinica were isolated as the most frequent species, followed by Nocardia nova isolated from 6 patients. Seventeen patients died, giving a crude morality rate of 56.7% and a 1-year survival rate of 55.4%. The 1-year survival rates in the groups with and without immunosuppressant agents were 41.7% and 59.7%, respectively, showing that the outcome of those receiving immunosuppressants tended to be poorer than those not receiving them. Conclusion Pulmonary nocardiosis developed as an opportunistic infection in most cases. The outcome was relatively poor, with a 1-year survival rate of 55.4%, and it was particularly poor in patients treated with immunosuppressant agents. Pulmonary nocardiosis should always be considered in patients presenting with an opportunistic respiratory infection, and an early diagnosis requires sample collection and Gram staining.
- Published
- 2017
- Full Text
- View/download PDF
20. Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis.
- Author
-
Akimoto M, Yunoue S, Otsubo H, Yoshitama T, Kodama K, Matsushita K, Suruga Y, Kozako T, Toji S, Hashimoto S, Uozumi K, Matsuda T, and Arima N
- Subjects
- Adult, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid drug therapy, CD4-Positive T-Lymphocytes drug effects, Female, Humans, Immunoassay methods, Immunosuppressive Agents adverse effects, Infections etiology, Joints physiopathology, Male, Middle Aged, Phytohemagglutinins pharmacology, Predictive Value of Tests, Risk, Severity of Illness Index, Adenosine Triphosphate blood, Arthritis, Rheumatoid complications, CD4-Positive T-Lymphocytes metabolism, Infections complications
- Abstract
Objective: The ability of the ImmuKnow (Cylex) assay to predict the risk of infection in rheumatoid arthritis (RA) patients receiving synthetic or biological disease-modifying antirheumatic drugs (DMARDs) was examined., Methods: The amount of adenosine triphosphate (ATP) produced by CD4+ cells in response to phytohemagglutinin was measured in whole blood from 117 RA patients without infection versus 17 RA patients with infection, and compared with results in 75 healthy controls., Results: The mean ATP level was significantly lower in patients with infection compared to both healthy controls (P < 0.0005) and patients without infection (P = 0.040). Also, the mean ATP level in patients without infection was significantly lower than that in healthy controls (P = 0.012). There was no correlation between the ATP level and the Disease Activity Score in 28 joints., Conclusion: ImmuKnow assay results may be effective in identifying RA patients at increased risk of infection, but the results showed no correlation with RA activity. Larger studies are required to establish the clinical advantages of this assay in RA treatment.
- Published
- 2013
- Full Text
- View/download PDF
21. Acute myelogenous leukemia with Leptotrichia trevisanii bacteremia.
- Author
-
Kumagai J, Takiguchi Y, Shono K, Suruga Y, Akiba Y, Yamamoto K, and Terano T
- Subjects
- Aged, Bacteremia diagnosis, Female, Fusobacteriaceae Infections diagnosis, Humans, Immunocompromised Host, Opportunistic Infections diagnosis, Bacteremia complications, Fusobacteriaceae Infections complications, Leptotrichia isolation & purification, Leukemia, Myeloid, Acute complications, Opportunistic Infections complications
- Abstract
A 74-year-old woman visited an otolaryngology clinic with pharyngeal pain, and was diagnosed with a peritonsillar abscess. She received antibiotics and underwent incisional drainage, but displayed high white blood cell and blast cell counts, and was referred to our hospital. Gram-negative rods (Leptotrichia trevisanii) were detected in blood cultures performed on admission. She was diagnosed with bacteremia and acute myelogenous leukemia (FAB classification: M1). After antibiotic therapy, she temporarily recovered from the bacteremia, but subsequently died on day 34. Although Leptotrichia trevisanii bacteremia is extremely rare, clinicians should consider it in cases involving immunocompromised patients with oral lesions.
- Published
- 2013
- Full Text
- View/download PDF
22. Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders.
- Author
-
Kozako T, Akimoto M, Toji S, White Y, Suzuki S, Arima T, Suruga Y, Matsushita K, Shimeno H, Soeda S, Kubota R, Izumo S, Uozumi K, and Arima N
- Subjects
- Adult, Aged, Aged, 80 and over, Gene Products, tax immunology, Gene Products, tax metabolism, Genetic Variation, HLA-A Antigens chemistry, HLA-A Antigens immunology, HLA-A Antigens metabolism, Histocompatibility Testing, Humans, Middle Aged, Protein Binding, Viral Envelope Proteins immunology, Viral Envelope Proteins metabolism, Young Adult, Autoimmune Diseases immunology, Epitopes immunology, Epitopes metabolism, Human T-lymphotropic virus 1 immunology, Human T-lymphotropic virus 1 metabolism, Paraparesis, Tropical Spastic immunology, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism
- Abstract
Human T-cell lymphotropic virus type I (HTLV-1) causes adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The different patterns of clinical diseases are thought to be linked to immunogenetic host factors. A variety of autoimmune diseases, such as Sjögren's syndrome, have been reported in persons infected with HTLV-1, although the precise relationship between these disorders and HTLV-1 infection remains unknown. There is no report on the repertoire of HTLV-1-specific CD8+ T-cells in HAM/TSP patients or carriers with autoimmune diseases, both characterized by an abnormal immune state. In this study, to characterize HTLV-1-specific CD8+ T-cells in asymptomatic HTLV-1 carriers, HAM/TSP patients and carriers with autoimmune diseases, we examined the frequency and diversity of HTLV-1-specific CD8+ T-cells using HTLV-1 tetramers. HTLV-1 Env-specific CD8+ T-cells were significantly more frequent in HAM/TSP and carriers with autoimmune diseases compared with asymptomatic HTLV-1 carriers, while the frequency of HTLV-1 Tax-specific CD8+ T-cells was not significantly different among them. CD8+ cells binding to HTLV-1 Tax tetramers in carriers with autoimmune diseases were significantly reduced compared with HAM/TSP patients. This study demonstrates the importance of CD8+ T-cells recognizing HTLV-1 Env-tetramers in HAM/TSP patients and carriers with autoimmune diseases, thereby suggesting that the diversity, frequency and repertoire of HTLV-1 Env-specific CD8+ T-cell clones may be related to the hyperimmune response in HAM/TSP and carriers with autoimmune diseases, although different immunological mechanisms may mediate the hyperimmunity in these conditions., (Copyright © 2011 Wiley-Liss, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
23. Stevens-Johnson syndrome induced by mizoribine in a patient with systemic lupus erythematosus.
- Author
-
Matsushita K, Ozaki A, Inoue H, Kaieda T, Akimoto M, Satomura A, Arima N, Hamada H, Suruga Y, Aoki N, Fujiwara H, and Tei C
- Subjects
- Adult, Cyclophosphamide therapeutic use, Cyclosporine therapeutic use, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Leukoencephalopathy, Progressive Multifocal etiology, Leukoencephalopathy, Progressive Multifocal pathology, Lupus Nephritis drug therapy, Lupus Nephritis pathology, Prednisolone therapeutic use, Stevens-Johnson Syndrome drug therapy, Stevens-Johnson Syndrome pathology, Treatment Outcome, Immunosuppressive Agents adverse effects, Lupus Nephritis complications, Ribonucleosides adverse effects, Stevens-Johnson Syndrome chemically induced
- Abstract
A 32-year-old Japanese woman, who had a treatment history of systemic lupus erythematosus (SLE) with lupus nephritis World Health Organization class IV for 11 months, visited our hospital due to fever, facial erythema, and erosion of the oral cavity on November 10, 2003. Her mucosal erosion and facial skin erythema progressed over the following week, and Stevens-Johnson syndrome was diagnosed due to pathological findings of the skin. Among the administrated drugs, only mizoribine, started 6 months earlier, produced a positive reaction in the drug lymphocyte stimulation test. Increased prednisolone and high dose intravenous gamma-globulin were given successfully. Cyclosporine at 50 mg was administered to control the SLE, followed by an increase to 100 mg on January 7, 2004. She suffered from abdominal pain, blindness, and convulsion on January 9. The magnetic resonance image of her brain prompted a diagnosis of reversible posterior leukoencephalopathy syndrome. After withdrawal of cyclosporine and control of hypertension, symptoms disappeared rapidly. Cyclophosphamide pulse therapy was successfully administrated to control lupus nephritis. This is the first report describing the relationship between Stevens-Johnson syndrome and mizoribine. Although the use of mizoribine is thought to be safe, careful observation is necessary.
- Published
- 2006
- Full Text
- View/download PDF
24. Interferon-alpha therapy following autologous peripheral blood stem cell transplantation for adult T cell leukemia/lymphoma.
- Author
-
Fujiwara H, Arima N, Akasaki Y, Ohtsubo H, Ozaki A, Kukita T, Matsushita K, Arimura K, Suruga Y, Wakamatsu S, Matsumoto T, Hidaka S, Eizuru Y, and Tei C
- Subjects
- Abdominal Neoplasms therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Doxorubicin administration & dosage, Doxorubicin analogs & derivatives, Etoposide administration & dosage, Female, Granulocyte Colony-Stimulating Factor therapeutic use, Human T-lymphotropic virus 1 drug effects, Humans, Immunologic Factors therapeutic use, Killer Cells, Natural immunology, Leukemia-Lymphoma, Adult T-Cell drug therapy, Leukemia-Lymphoma, Adult T-Cell immunology, Middle Aged, Nitrosourea Compounds administration & dosage, Remission Induction, T-Lymphocytes, Cytotoxic immunology, Transplantation, Autologous, Vincristine administration & dosage, Antiviral Agents therapeutic use, Hematopoietic Stem Cell Transplantation, Interferon-alpha therapeutic use, Leukemia-Lymphoma, Adult T-Cell therapy
- Abstract
In the present report, we describe a case of adult T cell leukemia/lymphoma (ATLL), a 58-year-old woman, successfully treated with interferon (IFN)-alpha following autologous peripheral blood stem cell transplantation (auto-PBSCT). The patient remains in remission with full performance status for more than 12 months. Auto-PBSCT reduced the abdominal lymphoma mass and IFN-alpha eliminated residual tumor cells, possibly through the induction of specific T-cell subsets expressing CD3, CD8 on their surfaces and either IFN-gamma or tumor necrosis factor (TNF)-alpha in cytoplasm. We have treated a total of 4 ATLL patients with auto-PBSCT, including the case presented herein. All other patients treated with auto-PBSCT were not followed by adjuvant chemotherapy or cytokine therapy and relapsed within 3 months after auto-PBSCT. This evidence suggests that the therapeutic success of the present case was attributable to the administration of IFN-alpha immunotherapy following auto-PBSCT., (Copyright 2002 S. Karger AG, Basel)
- Published
- 2002
- Full Text
- View/download PDF
25. Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
- Author
-
Makino M, Azuma M, Wakamatsu SI, Suruga Y, Izumo S, Yokoyama MM, and Baba M
- Subjects
- Adult, Aged, Antigen-Presenting Cells immunology, Antigens, CD analysis, B7-2 Antigen, Cell Differentiation, Cell Survival drug effects, Cells, Cultured, Dendritic Cells cytology, Dendritic Cells immunology, Female, Human T-lymphotropic virus 1 immunology, Humans, Intercellular Adhesion Molecule-1 analysis, Lymphocyte Activation immunology, Male, Membrane Glycoproteins analysis, Middle Aged, T-Lymphocytes cytology, T-Lymphocytes drug effects, T-Lymphocytes virology, Tumor Cells, Cultured, Lymphocyte Activation drug effects, Paraparesis, Tropical Spastic immunology, T-Lymphocytes immunology, Tetrazoles pharmacology, Thiophenes pharmacology
- Abstract
In a search for new anti-autoimmune agents that selectively suppress activation of autoreactive T cells, one such agent, 5-methyl-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide (CI-959-A), was found to be effective. This compound, which is known to suppress tumor necrosis factor alpha (TNF-alpha)-induced CD54 expression, inhibited the primary proliferative response of the T cell to antigen (Ag)-presenting cells (APCs) including allogenic dendritic cells (DCs), autologous Epstein-Barr virus-infected B cells, and human T lymphotropic virus type I (HTLV-I)-infected T cells. Autoreactive T cells from patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) spontaneously proliferate in vitro, and their activation is reported to be associated with CD54 expression. The spontaneous proliferation of T cells from patients with HAM/TSP was entirely blocked by CI-959-A. However, in this study, the T-cell proliferation in 15 patients with HAM/TSP was found to depend more extensively on major histocompatibility complex (MHC) class II and CD86 than on CD54 Ags. Since most important APCs for the development of HAM/TSP are DCs and HTLV-I-infected T cells, the effect of CI-959-A on DC generation and on the expression of surface molecules on activated T cells is examined. CI-959-A suppressed recombinant granulocyte-macrophage colony stimulating factor (GM-CSF)- and recombinant interleukin-4-dependent differentiation of DCs from monocytes and inhibited the expression of CD54 and, more extensively, MHC class II and CD86 Ags. CI-959-A showed little toxicity toward lymphoma or HTLV-I-infected T-cell lines or toward monocytes and cultured DCs. These results suggest that CI-959-A might be a potent anti-HAM/TSP agent.
- Published
- 1999
- Full Text
- View/download PDF
26. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
- Author
-
Suruga Y, Makino M, Okada Y, Tanaka H, De Clercq E, and Baba M
- Subjects
- Adenine pharmacology, Adenine therapeutic use, Animals, Anti-HIV Agents pharmacology, Cell Survival drug effects, Clone Cells, Female, Leukemia Virus, Murine physiology, Lymph Nodes pathology, Lymphocyte Activation drug effects, Mice, Mice, Inbred C57BL, Organophosphorus Compounds pharmacology, Specific Pathogen-Free Organisms, Spleen pathology, Tenofovir, Virus Replication drug effects, Zidovudine pharmacology, Zidovudine therapeutic use, Adenine analogs & derivatives, Anti-HIV Agents therapeutic use, Leukemia Virus, Murine drug effects, Murine Acquired Immunodeficiency Syndrome prevention & control, Organophosphonates, Organophosphorus Compounds therapeutic use
- Abstract
LP-BM5 murine leukemia virus (MuLV) infection causes severe immunodeficiency termed murine AIDS (MAIDS). The acyclic nucleoside phosphonates, (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) were examined, in comparison with zidovudine (AZT), for their inhibitory effect on the development of MAIDS. Although no significant difference in inhibition of LP-BM5 MuLV replication was identified between PMPA and PMEA in cell cultures, PMPA was obviously less cytotoxic to the host lymphocytes. None of the mice treated in vivo with 5 or 25 mg/kg of PMPA or 25 mg/kg of PMEA developed MAIDS at 5 weeks after viral infection. However at 9 weeks, none of the 25 mg/kg PMPA-treated mice progressed to MAIDS, except for one that developed mild MAIDS, whereas PMEA, even at 100 mg/kg, could not prevent disease progression. MAIDS-associated activation of lymphocytes and viral replication were drastically inhibited by PMPA treatment. These results indicate that PMPA is a highly effective antiretroviral agent in vivo.
- Published
- 1998
- Full Text
- View/download PDF
27. IL-2-induced growth of CD8+ T cell prolymphocytic leukemia cells mediated by NF-kappaB induction and IL-2 receptor alpha expression.
- Author
-
Arima N, Matsushita K, Suruga Y, Ohtsubo H, Fujiwara H, Hidaka S, Arimura K, Kukita T, Yamaguchi K, Fukumori J, and Tanaka H
- Subjects
- Blotting, Northern, CD8-Positive T-Lymphocytes drug effects, Cell Division drug effects, Flow Cytometry, Humans, Interleukin-2 biosynthesis, Interleukin-2 metabolism, Male, Middle Aged, NF-kappa B metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-rel, RNA, Messenger metabolism, Receptors, Interleukin-2 metabolism, Tumor Cells, Cultured, CD8-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes metabolism, Interleukin-2 pharmacology, Leukemia, Prolymphocytic metabolism, Leukemia, Prolymphocytic pathology, Leukemia, T-Cell metabolism, Leukemia, T-Cell pathology, NF-kappa B biosynthesis, Receptors, Interleukin-2 biosynthesis
- Abstract
The binding of interleukin-2 (IL-2) to its receptor on normal T cells induces nuclear expression of nuclear factor kappaB (NF-kappaB), activation of the IL-2 receptor (IL-2R) alpha chain gene, and cell proliferation. In the present study, the role of IL-2R signaling in the growth of CD8+ T cell prolymphocytic leukemia (T-PLL) cells has been investigated. Flow cytometry revealed that primary leukemia cells from a patient with CD8+ T-PLL expressed IL-2Ralpha and beta chains, and the cells showed a proliferative response and an increase in IL-2Ralpha expression on culture with exogeneous IL-2. Northern blot analysis failed to detect IL-2 mRNA, suggesting that IL-2 may act in a paracrine manner in vivo. Electrophoretic mobility-shift assays revealed that recombinant IL-2 increased NF-kappaB binding activity in nuclear extracts of the leukemia cells, and Northern blot analysis showed that IL-2 increased the abundance of mRNAs encoding the NF-kappaB components c-Rel and KBF1 in these cells. IL-2 binding analysis demonstrated that IL-2 markedly increased the number of low affinity IL-2Rs on the leukemia cells, without an effect on the number of high-affinity IL-2Rs. These results show that IL-2 is capable of inducing the nuclear expression of NF-kappaB in primary CD8+ T-PLL cells, and that this effect is mediated, at least in part, at a pretranslational level.
- Published
- 1998
- Full Text
- View/download PDF
28. Granulocyte-colony stimulating factor-induced proliferation of primary adult T-cell leukaemia cells.
- Author
-
Matsushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Kukita T, Suruga Y, Fukumori J, Matsumoto T, Kanzaki A, Yawata Y, and Tanaka H
- Subjects
- Aged, Cell Division drug effects, Female, Humans, Male, Middle Aged, Neutropenia chemically induced, RNA, Messenger analysis, Granulocyte Colony-Stimulating Factor therapeutic use, Leukemia, T-Cell pathology, Neutropenia drug therapy
- Abstract
Granulocyte-colony stimulating factor (G-CSF) is known to induce proliferation and differentiation of granulocyte progenitors, and is widely used to treat neutropenia induced by intensive chemotherapy for malignant lymphoma or adult T-cell leukaemia/lymphoma (ATL). G-CSF is thought not to stimulate malignant lymphoid cells. In the present study we examined the ability of G-CSF to induce in vitro growth of primary ATL cells from 14 patients (nine acute-type, two chronic-type and three lymphoma-type), and we analysed the in vivo counts of ATL cells in patients who received G-CSF for neutropenia. FACS analysis using phycoerythrin-labelled recombinant G-CSF demonstrated that ATL cells from 11/14 patients express some G-CSF receptor (G-CSFR), with a range between 5.4% and 87.3%. Cells expressing G-CSFR also expressed CD4. Reverse polymerase chain reaction (PCR) analysis demonstrated expression of G-CSFR messenger RNA in G-CSFR expressing cells. Leukaemic cells derived from seven (four acute-type, one chronic-type and two lymphoma-type) of the 14 patients proliferated in vitro in response to G-CSF, as measured by [3H]thymidine incorporation; maximum responses were at G-CSF concentrations of 10-100 ng/ml. Nine of 14 patients receiving rG-CSF for neutropenia were analysed retrospectively for ATL cell numbers. Four patients whose primary tumour cells proliferated in response to rG-CSF in vitro showed a significant increase in ATL cell count after administration of rG-CSF (P = 0.038), whereas five patients whose leukaemic cells did not proliferate in vitro showed no significant increase in ATL cell count. G-CSF can stimulate proliferation of ATL cells which may complicate therapy for this disease.
- Published
- 1997
- Full Text
- View/download PDF
29. [The etiology of acute lower respiratory tract infections in infants].
- Author
-
Ishiwada N, Sugimoto K, Uehara S, Koori Y, Suruga Y, Numazaki Y, Suzuki H, and Niimi H
- Subjects
- Acute Disease, Bacterial Infections, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Pneumonia, Mycoplasma, Respiratory Tract Infections virology, Virus Diseases, Respiratory Tract Infections microbiology
- Abstract
The etiology of acute lower respiratory tract infections (ALRI) was studied in pediatric inpatients under 2 years of age admitted to Chiba Municipal Hospital between June 1994 and March 1995. Eighty-seven patients, 99 episodes were investigated for bacterial infection with the use of blood culture and washed sputum culture, for viral infection with the use of virus isolation, antigen detection and antibody assays, for Mycoplasma pneumoniae infection with the use of antibody assay and for Chlamydia infection with the use of antigen detection. Pathogens were identified in 71 (71%) of the 99 episodes. Evidence of bacterial infection was detected in 43 episodes (43%), viral infection in 37 episodes (37%), Mycoplasma pneumoniae infection in 4 episodes (4%) and Chlamydia infection 3 episodes (3%). The major bacterial pathogens were H. influenzae, M. (B) catarrhalis and S. pneumoniae. RS virus and influenza virus epidemics occurred during the winter. A mixed bacterial and viral infection was documented in 13 episodes (13%). RS virus infection was common in infants up to 6 months old. Mixed bacterial and influenza virus infections were common in 1 or more year old children. Virus isolation was useful for the grasp of the viral epidemic. Bacterial associated infections were common in children under 2 years of age with ALRI. Washed sputum culture and sputum gram stains' were useful for the treatment of infant ALRI.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.